Las resistencias bacterianas: ¿Algo más que un problema clínico? La resistencia del enterococo a la vancomicina como ejemplo

Medicina Clinica

Volumn 112, Issue 14, 1999, Pages 553-555

  Aymerich, Marta ^a   García Altés, Anna ^a   Jovell, Albert J ^a  

^a Catalan Agency for Health Technology Assessment and Research   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; DISEASE PREDISPOSITION; DRUG SCREENING; ENTEROCOCCUS; HOSPITAL COST; HOSPITAL INFECTION; PATHOPHYSIOLOGY; PATIENT EDUCATION; PERSONAL HYGIENE; PRACTICE GUIDELINE; HUMAN; REVIEW;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS; HUMANS; VANCOMYCIN;

EID: 0033599677     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Krause RM. The origin of plagues: old and new. Science 1992; 257: 1.073-1.078.
2. Kunin CM. Resistance to antimicrobial drugs - a worldwide calamity. Ann Intern Med 1993; 118: 557-561.
3. Tomasz A. Multiple-antibiotic-resistant pathogenic bacteria -a report on the Rockefeller University workshop. N Engl J Med 1994; 330: 1.247-1.251.
4. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
5. CDC. Staphylococcus aureus with reduced susceptibility to vancomycin-United States, 1997. MMWR 1997; 46: 765-766.
6. Pechère JC. La microbiologie des infeccions nosocomiales. Bull Acad Natl Med 1993; 177: 705-718.
7. López P, Salas R, Vinuesa T, Gómez H. Resistencia a vancomicina en E. faecalis aislados de muestras clinicas. Rev Esp Quimiot 1993; 6: 82-83.
8. Frieden TR, Munsiff S, Low DE, Willey BM, Williams G, Faur Y et al. Emergence of vancomycin-resistant enterococci in New York City. Lancet 1993; 342: 76-79.
9. Torres C, Reguera JA, Sanmartin MJ, Pérez-Diaz JC, Baquero F. Van A-mediated vancomycin-resistant Enterococcus spp., in sewage. J Antimicrob Chemother 1994; 33: 553-561.
10. Bates J, Jordens JZ, Griffiths DT. Farm animals as a putative reservoir for vancomycin-resistant enterococcal infection in man. J Antimicrob Chemother 1994; 34: 507-514.
11. CDC. Nosocomial enterococci resistant to vancomycin: United States, 1989-1993. National Nosocomial of enterococcal infections surveillance. MMWR 1993; 42: 597-599.
12. US Congress, Office of Technology Assessment. Impacts of antibiotic-resistant bacteria. OTA-H-629. Washington, DC: US Government Printing Office, septiembre de 1995.
13. Alvarez F, De la Cal MA, Insausti J, Palomar M, Olaechea P. Estudio nacional de vigilancia de infección nosocomial en servicios de medicina intensiva. Envin-Uci. Informe 1996. Grupo de Trabajo de Enfermedades Infecciosas de la Sociedad Española de Medicina Intensiva y Unidades Coronarias (SEMIUC), 1996.
14. Aymerich M, García-Altés A, Jovell AJ. Revisió de l'evidència cientifica de les implicacions clíniques i econòmiques de la resistència a la vancomicina en enterococs. Barcelona: Agència d'Avaluació de Tecnologia Mèdica. Servei Català de la Salut. Departament de Sanitat i Seguretat Social. Barcelona: Generalitat de Catalunya, gener de 1998.
15. Boyce JM, Opal SM, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB et al. Outbreak of multidrug-resistant Enterococcus faecium with transferable van B class vancomycin resistance. J Clin Microbiol 1994; 32: 1.148-1.153.
16. Rhinehart E, Smith NE, Wennersten C, Gorss E, Freeman J, Eliopoulos GM, Moellering RC Jr, Goldmann DA. Rapid dissemination of β-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward. N Engl J Med 1990; 323: 1.814-1.818.
17. Chadwick PR, Oppenheim BA. Vancomycin-resistant enterococci and bedpan washer machines. Lancet 1994; 344: 685.
18. Freeman R, Kearns AM, Lighttfoot NF. Heat resistance of nosocomial enterococci. Lancet 1994; 344: 54-65.
19. Livornese LL, Dias S, Samel C, Romanowski B, Taylor S, May P et al. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers. Ann Intern Med 1992; 117: 112-116.
20. Orr KE, Gould FK, Perry JD, Ford M, Morgan S, Sisson PR et al. Therapeutic beds: the Trojan horses of the 1990s? Lancet 1994; 344: 65-66.
21. Neu HC. The crisis in antibiotic resistance. Science 1992; 257: 1.064-1.072.
22. Holmberg SD, Osterholm MT, Senger KA, Cohen ML. Drug-resistant Salmonella from animals fed antimicrobials. N Engl J Med 1984; 311: 617-622.
23. Spika JS, Waterman SH, Hoo GWS, St. Louis ME, Pacer RE, James SM et al. Chloramphenicol-resistant Salmonella newport traced through hamburger to dairy farms. N Engl J Med 1987; 316: 565-570.
24. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987; 9: 1.065-1.078.
25. Phelps CE. Bug/drug resistance. Sometimes less is more. Med Care 1989; 27: 194-203.
26. Stiglitz JE. La economía del sector público. Barcelona: Antoni Bosch Editors, 1988.
27. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. Nueva York: Oxford University Press, 1987.
28. Jovell AJ, Aymerich M, García-Altés A, Serra Prat M. Guía de práctica clinica del tratamiento erradicador de la infección por Helicobactor pylory asociada a la úlcera duodenal en atención primaria. Barcelona: Agència d'Avaluació de Tecnología Mèdica. Servei Català de la Salut. Departament de Sanitat i Seguretat Social. Generalitat de Catalunya. Septembre de 1998. BR98002.
29. HARMET project. Harmonization by Consensus of the Methodology for Economic Evaluation of Health Technologies in the European Union. Med Care 1996; 34: DS182-DS188.
30. Report from the EUR-ASSESS project. EUR-ASSESS project subgrup on dissemination and evaluation of impact. Int J Technol Assess Health Care 1997; 13: 220-286.
31. Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Guidelines for economic evaluation of pharmaceutical: Canada. Ottawa: CCOHTA, 1994.
32. Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Toronto: Ontario Ministry of Health, 1994.
33. England and Wales Department of Health. Guidelines on good practice in the conduct of economic evaluation of medicines. Londres: Department of Health, 1994.
34. Gold MR, Siegel JE, Russell LB, Weinstein MC, editores. Cost-effectiveness in health care and medicine. Nueva York: Oxford University Press, 1996.
35. Granados A. Convocatoria ATTM 1998: nuevamente de las ideas a la acción. Informatiu ATTM Agència d'Avaluació de Tecnologia Mèdica, junio-agosto 1998; 14: 1-3.
36. Jovell AJ, Granados A, Teira N. Developing funding research priorities to meet policy-making needs: the experience of Catalonia. Estocolomo, Suecia: First International Conference on Priorities in Health Care. Estocolmo: octubre 1996.